Zila Expands International Market of Ester-C(R) into Korea and Taiwan; Lohaspia, Inc. Signs Distributor Agreement
April 06 2006 - 8:30AM
Business Wire
Zila, Inc.'s (Nasdaq: ZILA), wholly-owned subsidiary, Zila
Nutraceuticals, Inc., has signed an agreement with Lohaspia, Inc.,
to distribute its Ester-C advanced vitamin C ingredient in Korea
and Taiwan. Both the Korean and Taiwan markets are among the top
five largest markets for vitamins outside the United States and
have been growing rapidly. "The introduction of Ester-C into Korea
and Taiwan represents significant progress in the execution of Zila
Nutraceuticals' aggressive international growth plan," said Douglas
D. Burkett, Ph.D., Chairman, Chief Executive Officer and President
of Zila, Inc. "We are very excited about this new growth
opportunity and fully committed to bringing the benefits of Ester-C
to the people of Korea and Taiwan. We expect Lohaspia to quickly
become one of our top customers." About Lohaspia Founded in 2000,
Lohaspia is headquartered in Seoul, South Korea and has sales
representatives located throughout Korea and Taiwan. The company
provides distribution services for food, vitamins and dietary
supplements and has an established track record of successful
product introductions similar to Ester-C. "We are very excited
about our partnership with Zila and feel very confident that we can
make Ester-C the number one branded ingredient in the Korean and
Taiwanese supplement market," said Rick Seo, Chief Executive
Officer of Lohaspia. About Ester-C Ester-C calcium ascorbate is an
advanced form of vitamin C. Unlike other forms of vitamin C,
Ester-C is non-acidic, so it's gentle on the stomach. Ester-C is a
readily absorbed form of vitamin C that helps support immune
health, heart health, joint health and vision. For more information
about Ester-C, visit www.ester-c.com. Ester-C is the registered
trademark of Zila Nutraceuticals, Inc. Information and statements
regarding dietary supplements have not been evaluated by the Food
and Drug Administration and are not intended to diagnose, treat,
cure, or prevent any disease. About Zila Zila, Inc., headquartered
in Phoenix, is an innovator in preventative healthcare technologies
and products, focusing on enhanced body defense and the detection
of pre-disease states. Zila has three business units: -- Zila
Biotechnology, a research, development and licensing business
specializing in pre-cancer/cancer detection through its patented
Zila Tolonium Chloride and OraTest(R) technologies. -- Zila
Pharmaceuticals, marketer of products to promote oral health and
prevent oral disease, including ViziLite(R) Plus oral lesion
identification kits and Peridex(R) prescription periodontal rinse.
-- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and
Ester-E(TM), branded, highly effective forms of Advanced Protection
vitamins C and E. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, margins,
profitability, cash flows and capital needs, the ability of the
Company to maintain required cash flows and cash availability to
implement its business plan and appreciation in the market value of
Zila's common stock. Such factors include, but are not limited to:
increased competition from current competitors and new market
entrants; the Company's ability to maintain, expand, or in certain
cases, regain distribution within new or existing channels of trade
for its products. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Report on Form 10-K
for its fiscal year ended July 31, 2005, filed with the Securities
and Exchange Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024